Pharmaceuticals

$GLAND is an important example of how earnings growth can become a stock-market catalyst. Its Q1 FY27 consolidated net profit increased 47% YoY to ₹317 crore, while revenue from operations rose about 20% to ₹1,800 crore. Adjusted EBITDA increased 37% and the margin was around 28%. The company’s CDMO business and US-market strength were important contributors. Beginners should not look only at the percentage rise in profit. Ask why profit increased. Is the growth coming from sustainable revenue, better margins, one-time gains, or cost reductions? Gland Pharma demonstrates the importance of examining revenue growth + EBITDA margin + PAT growth + business mix together. Also note that after a strong share-price rally, valuation and expectations become important; good results do not automatically mean the stock is cheap.